In locally recurrent rectal cancer, neoadjuvant chemo-reirradiation plus surgery with IOERT showed no grade 4–5 toxicities ...
AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...
China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...
At the San Antonio Breast Cancer Symposium, investigators reported findings from a retrospective study exploring whether ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...
Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...
Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results